[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of Vienna\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":674},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,141,0,25,[9,43,74,98,128,164,189,215,246,282,305,329,354,376,396,423,456,481,513,538,559,585,608,633,652],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100652392","telesdystocia-tele-support-vs-cognitive-aid-in-simulated-shoulder-dystocia-100652392",false,"NCT07772102","TelesDystocia: Tele-Support vs. Cognitive Aid in Simulated Shoulder Dystocia","TelesDystocia: A Randomized Controlled Simulation Trial Comparing Remote Tele-Support Versus a Standard Cognitive Aid for the Management of Shoulder Dystocia","TelesDystocia","Inclusion:\n\n* Adult healthy healthcare providers (paramedics, emergency physicians, midwives, nurses)\n* Working in teams of at least two persons\n* Fluent in German (the cognitive aid is provided in German)\n\nExclusion:\n\n* Training in shoulder dystocia management (McRoberts, suprapubic pressure, Gaskin) in the preceding six months\n* Not fluent in German",true,"ALL","18 Years",{"count":22,"type":23},52,"ESTIMATED","INTERVENTIONAL",[26],"NA","Shoulder dystocia is an unpredictable, time-critical obstetric emergency requiring immediate recognition and rapid execution of established maneuvers. To date, there is no published evidence evaluating remote real-time support for the management of shoulder dystocia, which could be especially relevant for providers not frequently confronted with obstetric emergencies.\n\nThis prospective, randomized, controlled, simulation-based trial compares healthcare providers' performance in managing a standardized shoulder dystocia scenario when supported by remote tele-assistance versus a standard cognitive aid. Teams of at least two healthcare providers manage a standardized scenario on the Laerdal MamaBirthie Task Trainer, with a trained study team member playing the laboring patient. Successful delivery requires completion of three predefined external maneuvers and one internal maneuver.\n\nTeams are randomized to Group A (cognitive aid: a standardized visual reference tool with written instructions and pictograms) or Group B (remote tele-support: live video guidance from a credentialed obstetric expert via Signal). The primary outcome is the total performance score (0-25 points). Secondary outcomes include cognitive load (NASA-TLX), usability (System Usability Scale), and subjective experience and communication quality (5-point Likert scales).",[29],"Shoulder Dystocia","NOT_YET_RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":23},"2026-08-25",{"date":38,"type":23},"2027-01-30",{"name":40,"class":41},"Medical University of Vienna","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100652194","early-predictors-of-bronchopulmonary-dysplasia-in-extremely-preterm-infants-100652194","NCT07771387","Early Predictors of Bronchopulmonary Dysplasia in Extremely Preterm Infants","Novel Predictive Indicators for Bronchopulmonary Dysplasia in Extremely Preterm Infants","EPIRESP","Inclusion Criteria:\n\n* Preterm infants born at \\\u003C26 weeks' gestational age, as determined by the best obstetric estimate based on the first day of the last menstrual period and\u002For first-trimester ultrasonography.\n* Admitted to the neonatal intensive care unit (NICU) of the Medical University of Vienna immediately after birth.\n* Written informed consent obtained prospectively from a parent or other legally authorized representative prior to study participation.\n\nExclusion Criteria:\n\n* Major congenital anomaly or anticipated alternative cause for respiratory failure.",{"count":52,"type":23},140,"OBSERVATIONAL","Bronchopulmonary dysplasia (BPD) remains one of the most common complications in extremely preterm infants despite advances in neonatal intensive care. Early identification of infants at high risk for BPD could facilitate individualized treatment strategies and improve long-term respiratory outcomes. However, current prediction models rely primarily on conventional clinical variables and have limited predictive accuracy.\n\nThis prospective observational study aims to evaluate the predictive value of novel physiological, imaging, and biomarker-based indicators for the development of BPD in infants born before 26 weeks of gestation. Participants admitted to the neonatal intensive care units of the Medical University of Vienna will undergo non-invasive assessments during routine clinical care. These include respiratory function monitoring during neonatal transition, lung ultrasound, diaphragmatic ultrasound, targeted neonatal echocardiography, forced oscillation technique, neurally adjusted ventilatory assist-derived diaphragmatic electrical activity, electrical impedance tomography, and proteomic analyses of plasma and tracheal aspirate samples.\n\nThe association between these novel indicators and respiratory disease severity will be assessed using the Respiratory Severity Score (RSS). Their ability to predict BPD will be evaluated using receiver operating characteristic (ROC) analysis and uni- and multivariable logistic regression models. Predictive performance will be assessed using the C-statistics.\n\nThe primary objectives are to determine the correlation between the novel indicators and the RSS and to evaluate their diagnostic accuracy for predicting BPD. Secondary objectives include identifying the combination of indicators that provides the best prediction of BPD, evaluating longitudinal changes in respiratory and cardiovascular parameters during the neonatal period, assessing the effects of respiratory interventions and treatments on these indicators, and investigating associations with survival and major neonatal morbidities.\n\nA total of 140 extremely preterm infants is planned for inclusion in the study. The results are expected to improve early risk stratification and contribute to the development of individualized strategies for preventing and managing BPD.",[56],"Bronchopulmonary Dysplasia",[56,58,59,60,61,62,63,64,65],"Infant, Extremely Premature","Lung","Ultrasonography","Echocardiography","Electric Impedance Tomography","Diaphragm","Proteomics","Respiration","2026-08-14",{"date":68,"type":34},"2026-08-18",{"date":70,"type":23},"2026-09-01",{"date":72,"type":23},"2030-06-30",{"name":40,"class":41},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100649238","fish-oil-and-hdl-function-in-patients-on-maintenance-hemodialysis-100649238","NCT07730385","Fish Oil and HDL Function in Patients on Maintenance Hemodialysis","Mechanistic Effects of n-3 Polyunsaturated Fatty Acid Supplementation on HDL Function in Patients Receiving Maintenance Hemodialysis (EFFLUX-HD): Study Protocol for a Randomized, Open-label, Crossover Trial","EFFLUX-HD","Inclusion Criteria:\n\n* age ≥ 18 years\n* receiving maintenance in-center hemodialysis\n* able to provide written informed consent\n* clinically stable condition (no hospitalization within 4 weeks prior to baseline)\n\nExclusion Criteria:\n\n* inability or unwillingness to provide informed consent\n* known hypersensitivity or intolerance to fish oil or n-3 PUFA-containing products\n* use of n-3 PUFA supplements at baseline or within the preceding 8 weeks\n* pregnancy\n* acute infection, hospitalization or major inflammatory condition at the time of baseline assessment\n* any condition that, in the investigator's opinion, would make participation unsafe or interfere with study participation or data interpretation\n* inherited lipid metabolism disorders",{"count":83,"type":23},40,[26],"Patients who receive maintenance hemodialysis have a very high risk of cardiovascular disease, and standard cholesterol-lowering treatments such as statins have not been shown to reduce cardiovascular events in this group. A recent clinical trial (PISCES) found that high-dose omega-3 fatty acids (fish oil) reduced cardiovascular events in hemodialysis patients, but the reason for this benefit is not understood.\n\nOne possible explanation is that, in kidney failure, high-density lipoprotein (HDL) no longer works normally. This study investigates whether omega-3 fatty acid supplementation improves the function of HDL in people on maintenance hemodialysis.\n\nForty adults on maintenance hemodialysis will take part. Each participant receives fish oil (4 g per day) for 8 weeks and also has an 8-week period without supplementation; participants are randomly assigned to the order of these two periods (crossover design), for a total of 16 weeks each. The main measure is cholesterol efflux capacity, a laboratory test of how well HDL removes cholesterol from cells. The study also examines other markers of HDL quality.\n\nThis is an exploratory, mechanistic study. Its aim is to determine whether omega-3 fatty acids change HDL function and to inform the design of larger future trials.",[87,88,89],"Kidney Failure Chronic","Cardiovascular Disease","HDL Cholesterol","2026-08-03",{"date":92,"type":34},"2026-08-04",{"date":94,"type":23},"2026-10",{"date":96,"type":23},"2027-02",{"name":40,"class":41},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100439452","infants-with-severe-acute-respiratory-distress-syndrome-the-prone-trial-100439452","NCT05002478","Infants With Severe Acute Respiratory Distress Syndrome: The Prone Trial","Short-Term Effect of Prone Positioning in Infants With Severe Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Patients hospitalized at Pediatric Intensive Care Unit (PICU) or Neonatal Intensive Care Unit (NICU) of the Medical University Vienna.\n* Patients aged \\>36 weeks (corrected gestational age) and \\\u003C24 months.\n* Patient intubated and mechanically ventilated for at least 6 hours, with an expected requirement of invasive ventilatory support for at least 12 hours.\n* Clinical picture strongly suggestive for acute bronchiolitis or pneumonia (fever, fine crackles, prolonged expiration, lung hyperinflation and\u002For findings of new infiltrates consistent with acute pulmonary parenchymal disease on chest X-ray).\n* Severe pediatric acute respiratory distress syndrome (ARDS), defined by OSI ≥12.3 (wean FIO2 to maintain SpO2 ≤ 97% to calculate oxygen saturation index).\n* Written informed consent obtained from parents.\n\nExclusion Criteria:\n\n* Clinical context\n\n  * Need for O2 supplementation to maintain SpO2\\>94% in the 4 weeks preceding hospitalization in the PICU\u002FNICU\n  * Cyanotic congenital heart disease Cardiogenic pulmonary edema\n  * Severe pulmonary hypertension\n  * Untreated pneumothorax\n  * Severe neurological abnormalities\n  * Other severe congenital anomalies such as congenital diaphragmatic hernia\n  * Ongoing cardiopulmonary resuscitation or limitation of life support\n* Contradictions for prone positioning (adapted from Guerin, C., et al., Prone positioning in severe acute respiratory distress syndrome. N Engl J Med, 2013. 368(23): p. 2159-68):\n\n  * Intracranial pressure \\>30 millimeters of mercury (mmHg) in supine position or cerebral perfusion pressure \\\u003C60 mmHg\n  * Massive hemoptysis requiring an immediate surgical or interventional radiology procedure\n  * Tracheal surgery or sternotomy during the previous 15 days\n  * Serious facial trauma or facial surgery during the previous 15 days\n  * Deep venous thrombosis treated for less than 2 days\n  * Cardiac pacemaker inserted in the last 2 days\n  * Unstable spine, femur, or pelvic fractures\n  * Use of extracorporeal membrane oxygenation (ECMO) before inclusion\n  * Lung transplantation\n  * Burns on more than 20% of the body surface\n* Other non-inclusion criteria\n\n  * Indication not to attempt resuscitation\n  * Patient already recruited for other clinical studies\n  * Patients who already received surfactant in the last 4 weeks\n  * Thoracic skin lesions or wounds on the thorax, where the EIT-electrode-belt would be placed","12 Months",{"count":107,"type":23},14,[26],"The main objective is to determine the short-term effect of prone positioning in infants with infection-associated severe acute respiratory distress syndrome. The investigators compare oxygenation parameters and measurements from electrical impedance tomography (EIT) and lung ultrasonography (LUS) in mechanically ventilated infants in prone position versus supine position after surfactant administration.",[111,112,113],"Acute Lung Injury\u002FAcute Respiratory Distress Syndrome (ARDS)","Surfactant Dysfunction","Infant",[115,116,117,118,119],"Acute Respiratory Distress Syndrome","Electrical Impedance Tomography","Lung Ultrasonography","Prone Position","Infants","RECRUITING",{"date":122,"type":34},"2026-08-06",{"date":124,"type":34},"2022-07-30",{"date":126,"type":23},"2027-12-31",{"name":40,"class":41},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":19,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":146,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},"100572152","education--care-in-rare-efficacy-of-targeted-psychoeducational-intervention-among-pediatric-rare-disease-patients-100572152","NCT06729554","Education & Care in RARE: Efficacy of Targeted Psychoeducational Intervention Among Pediatric Rare Disease Patients","Education & Care in RARE - Efficacy of Targeted Psychoeducational Intervention to Improve Knowledge About Rare Diseases and to Promote Mental Health Among Pediatric Rare Disease Patients","Inclusion Criteria:\n\n* Children and adolescents with a confirmed diagnosis of a rare disease with\n* Age 5-20 years, corresponding to a developmental age of 5-18 years\n* Existing medical care at a participating study center because of the rare disease\n* Voluntary participation and informed consent\n* Ability to complete the questionnaires\n* Ability to actively participate the intervention (psychoeducation)\n\nExclusion Criteria:\n\n* Moderate or severe cognitive impairment\n* Simultaneous admission of the child \u002F adolescent to a setting with high-frequency psychotherapeutic intervention (e.g. admission to psychosomatic medicine, child and adolescent psychiatry)\n* No informed consent\n* Language barrier of the child \u002F adolescent\n* Assumption that compliance is too low to attend all study appointments","5 Years","20 Years",{"count":138,"type":23},100,[26],"\"Rare Diseases\" is an umbrella term including more than 8.000 different diseases which individually affect only a small percentage of people. Rare diseases predominantly affect children and adolescents and are associated with high medical and psychosocial burden of disease.\n\nThe investigators invented Education \\& Care in RARE - a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases.\n\nThis study is a prospective, multicenter, randomized and controlled study with a waiting list. Aim of the study is to investigate the efficacy of Education \\& Care in RARE on knowledge about rare diseases and on mental health well-being in pediatric rare disease patients, compared to a control group.\n\nIn this study participants are randomized in an intervention group and a waiting list control group. Both study groups thus receive the psychoeducation with Education \\& Care in RARE and complete the identical questionnaires. Compared to the Intervention group, the waiting list control group receives the intervention with a time delay (8-12 weeks later) and has one additional appointment for questionnaire evaluation before start of the psychoeducation.",[142,143,144,145],"Orphan Diseases","Rare Disorders","Pediatric Diseases","Inborn Errors of Metabolism Disorders",[147,148,149,150,151,152,153,154],"Rare diseases","ultra-rare diseases","psychoeducation in pediatrics","psychoeducation for alle rare diseases","rare pediatric diseases","orphan diseases psychoeducation","rare disease burden","waiting list control study","2026-07-27",{"date":157,"type":34},"2026-07-28",{"date":159,"type":34},"2024-12-15",{"date":161,"type":23},"2028-12-01",{"name":40,"class":41},7,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":105,"enrollmentInfo":171,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":173,"conditions":174,"keywords":179,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":42},"100438450","comparison-of-computertomography-scan-electrical-impedance-tomography-and-ultrasound-of-the-lung-in-infants-100438450","NCT04989439","Comparison of Computertomography Scan, Electrical Impedance Tomography, and Ultrasound of the Lung in Infants","Comparison of Computertomography Scan, Electrical Impedance Tomography, and Ultrasound of the Lung in Infants - A Prospective Explorative Observational Study","Inclusion Criteria:\n\n* Patients hospitalized at the Department of Pediatrics of the Medical University of Vienna who will get a CT scan of the thorax.\n* Patients aged up to 12 months\n\nExclusion Criteria:\n\n* Unstable cardiovascular, respiratory and\u002For neurological conditions.\n* Sternotomy during the previous 15 days.\n* Thoracic skin lesions or wounds (including burns) on the thorax, where the EIT-electrode-belt would be placed.",{"count":172,"type":23},10,"The study focuses on regional lung examination, in particular on the differentiation between collapsed and hyperinflated lung areas. The purpose of the study is to elaborate common and discriminative elements between different lung imaging modalities in infants and to generate hypotheses for the bedside use of EIT and LUS in infants.",[175,176,177,60,178],"Infant ALL","Computed Tomography","Electric Impedance","Lung Injury",[180],"CT, electrical impedance tomography, ultrasound","2026-07-23",{"date":183,"type":34},"2026-07-24",{"date":185,"type":34},"2021-07-19",{"date":187,"type":23},"2028-12-31",{"name":40,"class":41},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":42},"100647665","evaluation-of-kidney-fibrosis-via-fapi-petct-100647665","NCT07712679","Evaluation of Kidney Fibrosis Via FAPI PET\u002FCT","Evaluation of Renal Renal Fibrosis Vie FAPI-PET-CT: a Prospective Non-randomized Open-label Single-center Pilot Study","Inclusion Criteria:\n\n* Histological workup of native kidney present\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Pregnancy",{"count":197,"type":23},30,[26],"Interstitial fibrosis is a hallmark of progression in chronic kidney disease (CKD), yet it can presently be assessed only by kidney biopsy, which is invasive and prone to sampling error.\n\nIn recent years the advances in molecular imaging, especially high spatial and temporal resolution of the scanners and the development of radiopharmaceuticals to visualize metabolic processes or immune cells have been significant, opening promising possibilities in multiple fields. It was demonstrated that in autoimmune diseases as Crohns disease the use of fibrosis markers, as 68Ga-FAPI tracer in PET\u002FMRI could adequately reflect the amount of fibrosis found in histologic work up of tissue specimens in the gut. Also first data in small studies including patients with chronic kidney disease showed promising results indicating that tracer uptake could reflect the degree of fibrosis.\n\nThis study aims to investigate the utility of PET\u002FCT imaging with a \\[68Ga\\]-DOTA.SA.FAPi tracer to reflect the degree of fibrosis found in the histological work up. We hypothesize that PET\u002FCT findings reflect histological found fibrotic changes in kidney biopsies, potentially offering a superior alternative due to its non-invasive nature and the possibility to capture the entire organ.",[201],"Chronic Kidney Disease",[203,204,205,206],"Chronic kidney disease","PET\u002FCT","FAPI Imaging","Fibrosis","2026-07-14",{"date":209,"type":34},"2026-07-17",{"date":211,"type":34},"2025-09-05",{"date":213,"type":23},"2027-09-01",{"name":40,"class":41},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":53,"phases":4,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":42},"100643020","balance-ards-deconvolution-by-bronchoalveolar-lavage-multiomics-and-radiomics-100643020","NCT07633366","BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics","Check the BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics Profiling and Radiomics","BALance","Inclusion Criteria:\n\n* male and female\n* aged 18 years or over\n* signed consent form\n* depending on the study group: Confirmed ARDS according to the Berlin criteria (see below, Groups B and D) Confirmed severe CAP requiring mechanical ventilation and intensive care (see below, Groups B and C) Ventilated patients without signs of ARDS (see below, Group E)\n\nExclusion Criteria:\n\n\\- under 18 years of age",{"count":224,"type":23},130,"4 Years","Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema. Pathomechanisms include barrier breakdown, immunopathology, haemostatic derailment and dysbiosis; however, the actual sequence of events and how they cumulatively lead to lung failure remains unclear. Although ARDS is frequently triggered by pneumonia, it can also occur as a result of trauma, aspiration or non-pulmonary causes. Importantly, ARDS is highly heterogeneous; growing evidence points to aetiology-specific pathomechanisms - a circumstance that explains why attempts to develop specific drugs or timely diagnostic markers have so far failed.\n\nA comprehensive analysis of key microenvironmental and haemostasis-related parameters of the lung, combined with multidimensional quantitative image features derived from chest CT scans (radiomics), will enable us to i) identify ARDS phenotypes with different biological characteristics and ii) generate new hypotheses regarding aetiology- or subgroup-specific mechanisms, molecular markers and therapeutic options.\n\nOur approach is based on ICU management of our patients guided by bronchoalveolar lavage fluid (BALF). Together with previously sampled cases and new samples collected as part of this study, our cohort will consist of patients with i) COVID-19-associated ARDS, ii) ARDS associated with other viral pneumonia, iii) ARDS associated with bacterial pneumonia, and iv) ARDS of non-pulmonary origin. Bacterial and fungal co-infections and superinfections are recorded in all patients and taken into account in the stratification. Patients with pneumonia without ARDS, as well as ventilated patients without underlying lung disease, serve as controls. To characterise the microbial lung microenvironment, the investigators combine data from routine microbiological diagnostics with microbiome sequencing and metabolomics. In addition, the investigators conduct comprehensive and longitudinal immune and haemostatic profiling by regularly analysing immune cells, cytokines and parameters of immune thrombosis in BALF and blood. Multi-omics integration then identifies phenotypic subgroups by merging all multimodal datasets - including radiomics. Selected samples from identified clusters are then further characterised using single-cell sequencing to uncover specific features\u002Fmarkers and pathomechanisms of the respective ARDS subtypes.\n\nAlthough it is clear that the pathogenesis of ARDS is multifactorial, comprehensive studies that integrate all relevant parameters are rare. Radiomics is increasingly recognised as a powerful tool for capturing the clinical status of ARDS in detail; however, to date, this imaging data has not been systematically linked to other omics readouts. The investigators aim to bridging this gap by conducting a thorough investigation across various ARDS aetiologies in the present study, incorporating all identifiable key factors.\n\nOur interdisciplinary team comprises basic immunologists, infectious disease and computational biologists, as well as clinicians with expertise in ARDS, infectious diseases, immunothrombosis and radiology.",[228],"ARDS (Acute Respiratory Distress Syndrome)",[230,231,232,233,234,235,236,237],"ARDS","BALF","COVID-19","Influenza","Co-Infection","Pneumonia","viral","bacterial","2026-07-08",{"date":240,"type":34},"2026-07-10",{"date":242,"type":23},"2026-07",{"date":244,"type":23},"2030-06-01",{"name":40,"class":41},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":253,"minAge":20,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":24,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},"100647012","the-impact-of-myo-inositol-on-glycemic-control-and-oxidative-stress-in-gestational-diabetes-mellitus-100647012","NCT07685015","The Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestational Diabetes Mellitus","The Impact of Myo-Inositol Supplementation on Glycemic Control and Oxidative Stress in Women With Gestational Diabetes Mellitus: A Randomized, Open-Label Pilot Study","Inclusion Criteria:\n\n* GDM diagnosis\n* at least one of the HAPO-Study criteria: 2h-oGTT → \\>153 mg\u002Fdl, 1h-oGGT → \\>180 mg\u002Fdl, fasting plasma glucose \\> 92 mg\u002Fdl\n* age between 18-45\n* single pregnancy\n\nExclusion Criteria:\n\n* T2DM\n* T1DM\n* Maturity Onset Diabetes of the Young (MODY)\n* Latent Autoimmune Diabetes in Adults (LADA)\n* pre pregnancy BMI \\>35\n* oral antidiabetic drugs\n* pre-existing renal disease\n* heart disease and other chronic medical disorders\n* allergies to any ingredients contained in the dietary supplements","FEMALE","45 Years",{"count":83,"type":23},[26],"The purpose of this clinical study is to investigate the potential effects of myo-inositol supplementation on changes in glycemic control parameters, oxidative stress, inflammatory biomarkers, psychometric markers, and body composition in participants with gestational diabetes mellitus (GDM).\n\nThe study duration is 3 to 3.5 months, depending on the time of GDM diagnosis. Before the active phase begins, there is a 10-day observation period during which participants' blood glucose levels are monitored using a continuous glucose monitoring device. In the subsequent 12-14-week study phase, participants will receive a supplement based on random group assignment. They will be allocated either to an intervention group (myo-inositol + folic acid) or a control group (folic acid). Both supplements will be taken until delivery.\n\nThe intervention group supplement contains 4 g myo-inositol and 400 μg folic acid (BIOGENA GmbH, Salzburg) and is to be taken twice daily with water - three capsules per meal. The control group supplement contains only 400 μg folic acid (BIOGENA GmbH, Salzburg) and is also taken twice daily, one capsule per meal. As this is a pilot study, both participants and study personnel will be aware of group assignments.\n\nBlood glucose measurements will be repeated mid-study (around the 33rd week of pregnancy) and at the end (37th week of pregnancy) using glucose sensors. To improve the evaluation of glucose measurements, participants will keep dietary logs during these periods.\n\nThree study visits are planned, during which the following assessments will be conducted. To determine the primary outcome, \"time in range (TIR)\" (time spent within the target glucose range), three glucose sensor measurements will be performed. At each visit, blood samples will be taken to analyze glycemic control parameters (hemoglobin A1c (HbA1c), fasting glucose, fasting insulin, Homeostasis Model Assessment (HOMA-IR), insulin dosage), oxidative stress markers (total antioxidant capacity, malondialdehyde levels), and inflammatory markers (interleukin-6 (IL-6), C-reactive protein (CRP)). Anthropometric measurements (weight gain, blood pressure, pulse) and body composition (Bioelectrical Impedance Analysis) will also be performed.\n\nAdditionally, maternal and fetal birth outcomes will be recorded, including cesarean section rates, fetal gestational weight, preterm birth rates, and neonatal hypoglycemia occurrence. To assess participants' well-being and physical activity, questionnaires will be distributed at the beginning and end of the study.",[259],"Gestational Diabetes Mellitus (GDM)",[261,262,263,264,265,266,267,268,269,270,271,272],"Gestational Diabetes Mellitus","GDM","Myo-Inositol","Continous Glucose Monitoring","CGM","Oxidative Stress","Inflammation","Glycemic Control","Inositol","MYO","MI","Pregnancy","2026-07-02",{"date":275,"type":34},"2026-07-06",{"date":277,"type":34},"2026-03-23",{"date":279,"type":23},"2027-07-01",{"name":40,"class":41},2,{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":292,"conditions":293,"keywords":297,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":42},"100643650","intensive-care-outcome-prediction-using-admission-carbohydrate-deficient-transferrin-100643650","NCT07632716","Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin","IMPACT - Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin A Prospective Single-center Cohort Study","IMPACT","Inclusion Criteria:\n\n* all patients ≥ 18 admitted to the Department of Emergency Medicine and subsequently transferred to an in-house intensive care unit (ICU)\n\nExclusion Criteria:\n\n* Patients transferred to other hospital departments prior to completion of intensive care\n* Patients admitted directly to the ICU without passing the ED\n* Patients admitted to intermediate care units\n* Patients with pre-existing or newly diagnosed hepatic cirrhosis\n* Patients with known or obvious pregnancy will be excluded.\n* Patients with no vascular access",{"count":291,"type":23},800,"The goal of this observational study is to learn whether hazardous alcohol consumption, measured objectively by carbohydrate-deficient transferrin (CDT) levels at intensive care unit (ICU) admission, is associated with worse outcomes in critically ill patients. The main question it aims to answer is:\n\nDo elevated CDT levels at ICU admission predict increased short-term mortality and adverse clinical outcomes in adult non-traumatic ICU patients? Participants admitted to the intensive care unit via the emergency department will have CDT levels measured as part of the study. Researchers will then collect and analyze clinical data, including mortality, duration of mechanical ventilation, delirium, ICU length of stay, renal replacement therapy, and ICU readmission rates, during hospitalization and follow-up.",[294,295,296],"Intensive Care (ICU)","Critical Illness","Alcohol Misuse",[298,295,299],"Alcohol-Related Disorders","Intensive Care Units",{"date":275,"type":34},{"date":273,"type":34},{"date":303,"type":23},"2028-07",{"name":40,"class":41},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100543556","association-of-anti-factor-xa-activity-with-venous-thromboembolism-in-critically-ill-patients-100543556","NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study",{"count":314,"type":23},1300,"The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[317,318,319],"Thrombosis","Pulmonary Embolism","Enoxaparin","2026-06-18",{"date":322,"type":34},"2026-06-23",{"date":324,"type":34},"2024-05-04",{"date":326,"type":23},"2027-08",{"name":40,"class":41},3,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":4},"100642829","comparison-of-tunneled-cuffed-dialysis-catheters-versus-arteriovenous-fistulae-in-elderly-or-multimorbid-patients-100642829","NCT07649083","Comparison of Tunneled Cuffed Dialysis Catheters Versus Arteriovenous Fistulae in Elderly or Multimorbid Patients","Inclusion Criteria:\n\n* Aged ≥60 years or \\\u003C60 years with a CCI Score \\>6\n* Patients with CKD G5 A1-3 with indication for hemodialysis\n* Stable clinical condition\n* Eligibility for both arteriovenous fistula on the upper extremities and TCC\n* Availability for follow-up\n* Written informed consent\n\nExclusion Criteria:\n\n* Uncontrolled infection and\u002For CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl) at screening\n* Poor overall health or malignancy not in remission at screening\n* Major surgery within 12 weeks before screening\n* Pre-existent vascular access\n* Patient not eligible for any one of the vascular access options\n* Endovascular arteriovenous fistula","99 Years",{"count":337,"type":23},220,[26],"Patients are randomly assigned to a study group. Depending on the study group, either an arteriovenous fistula or tunneled cuffed catheter (TCC) will be implanted, followed by continuous evaluation of the patients during the first year after initiating the vascular access. The evaluation includes statistical evaluation of all events, including loss of access, thrombosis, infection, loss of patency, increase in co-morbidities, e.g. congestive heart failure as well as quality of life. The implantation of the TCC is a standard procedure and it will be used only in accordance with the approved instructions of use on subjects who have signed an informed consent form. The surgery is a standard operation and it will be performed by specialized surgeons on subjects who have signed an informed consent form (No grafts will be used; implantation of a standard TCC, used at the Department of Nephrology). Both, an arteriovenous fistula or a TCC, will be used for routine chronic haemodialysis",[341,342,343,344,345],"End Stage Renal Failure, Hemodialysis","Vascular Access","Fistulas Arteriovenous","Haemodialysis Complication","Haemodialysis Patients","2026-06-11",{"date":348,"type":34},"2026-06-16",{"date":350,"type":23},"2026-08-01",{"date":352,"type":23},"2030-12-31",{"name":40,"class":41},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":374,"leadSponsor":375,"locationsCount":42},"100641241","impact-of-a-tunneled-hemodialysis-catheter-with-endexo-technology-on-catheter-dysfunction-compared-with-historical-catheter-dysfunction-data-in-standard-catheters-100641241","NCT07655544","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters (Silicone or Polyurethane): A Pilot Study","Inclusion Criteria:\n\n* Adult patients aged greater than 18 years\n* Written informed consent\n* Requirement for hemodialysis using a tunneled dialysis catheter\n\nExclusion Criteria:\n\n* Children aged less than 18 years\n* Uncontrolled infection; defined as positive blood culture in the past seven days before catheter insertion and\u002F or elevated C-reactive protein \\[CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl)\\] at screening",{"count":362,"type":23},50,[26],"There is evidence that central venous catheters made of the permanent and non-eluting integral polymer Endexo® are more resistant to intraluminal thrombosis. This has a direct reducing effect on catheter malfunctions. Indirectly, due to reduced handling of the dysfunctional catheter, this may lead to a diminished rate of catheter related infections. Since catheter malfunctions and infections represent leading complications in a dialysis population, dialysis catheters produced with Endexo® technology have the potential to have beneficial clinical effects. In addition to improving patient outcomes, this could also reduce overall costs. In this pilot study the tunneled hemodialysis catheter BioFlo Duramax with Endexo® technology (Merit Medical, Utah, USA) will be compared with historical catheter dysfunction rates in standard tunneled dialysis catheters (silicone or polyurethane) in chronic dialysis population.",[366,344,342,367,368,369,370,371],"Haemodialysis","Vascular Access Complication","ESRD (End Stage Renal Disease)","Dialysis Access Dysfunction","Dialysis Catheter","Dialysis Catheter Infections",{"date":320,"type":34},{"date":350,"type":23},{"date":126,"type":23},{"name":40,"class":41},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100638377","personalized-targeted-glioblastoma-therapies-by-ex-vivo-drug-screening-advanced-brain-tumor-therapy-clinical-trial-in-patients-scheduled-for-short-course-radiation-100638377","NCT07627334","Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN","ATTRACTION","Inclusion Criteria:\n\n* ECOG performance status 0-2\n* Newly diagnosed glioblastoma, IDH-wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System\n* Unmethylated MGMT promotor per local assessment\n* Successful PDC establishment and PDCs available for drug screening - based on inclusion in one of the following studies: (EK Nrs. (a) Medical University of Graz: 32-650 ex 19\u002F20; (b) Medical University of Vienna: 1407\u002F2021; (c) Karl Landsteiner University of Health Sciences: GS1-EK-4\u002F823-2022; (d) Kepler University Hospital Linz: 1323\u002F2022; (e) Medical University of Innsbruck 1003\u002F2023) and follow-up ethics covering the establishment of an Austrian GlioBank (EK Nrs. (a) Medical University of Graz: 36-253 ex 23\u002F24; (b) Medical University of Vienna: 2186\u002F2023; (c) Karl Landsteiner University of Health Sciences: GS3-EK-1\u002F211-2024; (d) Kepler University Hospital Linz: 1002\u002F2024; (e) Medical University of Innsbruck 1095\u002F2024)\n* Scheduled short-course radiotherapy with or without concomitant temozolomide\n* Written informed consent\n* No exclusion criteria\n\nExclusion Criteria:\n\n* Current participation in another therapeutic clinical trial.\n* Patients with a concurrent malignancy or malignancy within five years of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years.\n* Pregnant or lactating women.\n* Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n* Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells\u002Fmm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.\n* Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.",{"count":197,"type":23},[26],"Patients will receive in addition to standard histology analysis also the PDC- based drug screening.",[387],"Glioblastoma (GBM)","2026-05-31",{"date":390,"type":34},"2026-06-04",{"date":392,"type":23},"2026-06-01",{"date":394,"type":23},"2029-01-01",{"name":40,"class":41},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":405,"conditions":406,"keywords":410,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":42},"100638835","optimize-55---optimizing-impella-55-outcomes-through-advanced-data-science-100638835","NCT07619144","OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science","Clinical Outcomes and Adverse Events Associated With Microaxial Flow Pump Support: An Explorative Retrospective Study","OPTIMIZE","Inclusion Criteria:\n\n* Adult patients who were treated for cardiogenic shock and supported with an Impella 5.5 micro-axial flow pump\n* Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets\n\nExclusion Criteria:\n\n* Patients supported with an Impella 5.5 for indications other than cardiogenic shock (e.g., protected PCI or CABG)\n* Patients younger than 18 years\n* Patients with incomplete data, procedural records, or demographic information",{"count":138,"type":23},"The main goal of this observational, study is to develop a clinical decision support tool utilizing Impella 5.5 pump parameters to predict native heart recovery and prevent adverse events, by leveraging data science and real-world clinical data of cardiogenic shock patients.\n\nTherefore, secondary objectives are essential to consolidating a retrospective longitudinal analysis of Impella 5.5 pump data alongside ICU digital health record datasets to:\n\n1. Validate the Impella 5.5 placement signal by comparing it with ICU arterial line waveforms.\n2. Integrate pump data with ICU clinical data to identify patterns associated with therapy outcomes, including native heart recovery, heart replacement therapy, and mortality while on device support.\n3. Define clinical scenarios linked to hemolysis, HRAEs, and arrhythmias and develop predictive models to mitigate their occurrence.",[407,408,409],"Cardiogenic Shock","Mechanical Circulatory Support","Cardiogenic Shock Post Myocardial Infarction",[411,412,413,414,415],"cardiogenic shock","mechanical circulatory support","Impella 5.5","micro-axial flow pump","data science","2026-05-27",{"date":392,"type":34},{"date":419,"type":34},"2026-05-08",{"date":421,"type":23},"2029-05-30",{"name":40,"class":41},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":19,"minAge":430,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":24,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":42},"100637399","unilateral-ventilation-on-cardiopulmonary-bypass-during-cardiac-surgery-100637399","NCT07612709","Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery","Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery in Patients at Increased Risk for Severe Postoperative Pulmonary Complications","Inclusion Criteria:\n\n* Patients at increased risk for postoperative pulmonary complications\n* Major elective cardiac surgery\n* Prolonged duration of cardiopulmonary bypass\n* Patients older than 65 years of age\n* Informed consent\n\nExclusion Criteria:\n\n* Emergency\n* Urgent procedures\n* Patients with implanted pacemakers\n* Patients with internal cardioverter\u002Fdefibrillators\n* Decompensated cardiac disease\n* Pulmonary disease\n* Recent pneumonia\n* Need for temporary perioperative mechanical support\n* Patients not willing to participate\n* Treatment with inhaled nitric oxide","65 Years",{"count":432,"type":23},45,[26],"This study investigates if single lung ventilation on cardiopulmonary bypass can mitigate postoperative lung water accumulation determined by lung ultrasound in the ventilated lung as compared to the non-ventilated lung in patients at high-risk for developing severe pulmonary complications after cardiac surgery.",[436,437,438,439,440,441,442,443,444,445,446,447],"Lung Protective Ventilation","Cardiopulmonary Bypass","High-risk Cardiac Patients","Lung Ultrasound","Lung Water Assessment","Pulmonary Complications in Surgical Patients","Single-lung Ventilation","Chest X-ray for Clinical Evaluation","Electrical Impedance Tomography (EIT)","Lung Compliance","Oxygenation Indices","Biomarkers of Vascular Endothelial Injury","2026-05-24",{"date":450,"type":34},"2026-05-29",{"date":452,"type":23},"2026-10-01",{"date":454,"type":23},"2029-07-31",{"name":40,"class":41},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":464,"targetDuration":466,"studyType":53,"phases":4,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":480},"100640745","austrian-pbc-registry-100640745","NCT07598669","Austrian PBC Registry","Characterisation of Patients With Primary Biliary Cholangitis in Austria - A Prospective Registry and Biobank","PBC-AUT","Inclusion Criteria:\n\n* Age \\>18 years\n* Confirmed diagnosis of primary biliary cholangitis (at least two of the following three criteria must be fulfilled: persistent elevation of alkaline phosphatase above the upper limit of normal for at least 6 months; presence of antimitochondrial antibodies or PBC-specific antinuclear antibodies; characteristic histopathology)\n* Written informed consent for participation in the registry\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent",{"count":465,"type":23},500,"10 Years","The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden. Patients with primary biliary cholangitis treated at participating centres in Austria will be invited to take part in this prospective registry. Participation in an associated biobank is optional. Clinical and laboratory data will be collected, and patients will be followed regularly through scheduled clinic visits. In addition, biological samples (serum, plasma, and, if available, liver tissue) may be collected and stored in the biobank for future research.",[469,470,471],"Primary Biliary Cholangitis","Liver Cirrhosis","Portal Hypertension","2026-05-16",{"date":474,"type":34},"2026-05-20",{"date":476,"type":34},"2026-03-18",{"date":478,"type":23},"2040-12",{"name":40,"class":41},11,{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":24,"phases":491,"briefSummary":493,"conditions":494,"keywords":498,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":4},"100637582","early-phase-1-pain-induced-by-m-cresol-as-preservative-100637582","NCT07600814","Pain Induced by m-Cresol as Preservative","Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers","Inclusion criteria\n\n* Age between 18 and 70 years\n* Full legal capacity Exclusion criteria\n* Participant of another study, ongoing or within the last four weeks\n* Current medication intake (except hormonal contraception) or drug abuse\n* Female subjects: Positive pregnancy test or breastfeeding\n* Body temperature above 38°C, verified by infrared thermometer\n* Known allergic diseases, in particular asthmatic disorders and skin diseases\n* Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site","70 Years",{"count":490,"type":23},18,[492],"EARLY_PHASE1","Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.\n\nThis study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.",[495,496,497],"Pain","Acute Pain","Healthy Volunteer Study",[499,500,501,502,503,504],"m-Cresol","Preservative","Subcutaneous Injection","Human Pain Models","Experimental Pain Models","Nociception","2026-05-15",{"date":507,"type":34},"2026-05-22",{"date":509,"type":23},"2026-05-25",{"date":511,"type":23},"2026-06-08",{"name":40,"class":41},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":522,"conditions":523,"keywords":528,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":535,"leadSponsor":537,"locationsCount":42},"100640435","perception---super-early-neuroprognostication-in-ecpr-patients-100640435","NCT07584187","PERCEPTION - Super-Early Neuroprognostication in eCPR Patients","Super-Early Neuroprognostication in eCPR Patients: Feasibility of Automated Pupillometry and Cerebral Near-Infrared Spectroscopy - A Prospective Feasibility Study","PERCEPTION","Inclusion Criteria:\n\n* All patients ≥ 18 years evaluated for eCPR treatment at the Department of Emergency Medicine\n\nExclusion Criteria:\n\n* Return of spontaneous circulation before ECMO initiation.\n* Anatomical infeasibility for measurement, including but not limited to:\n* Severe facial trauma or deformity preventing the placement of the automated pupillometry device.\n* Scalp injuries, dressings, or conditions that interfere with the correct positioning of near-infrared spectroscopy (NIRS) sensors.\n* Pre-existing ocular conditions that preclude reliable pupillometry (e.g., enucleation, opaque cornea, or severe anisocoria unrelated to neurological status).",{"count":432,"type":23},"Background Extracorporeal cardiopulmonary resuscitation (eCPR) is a rescue therapy for a selected group of patients. Extracorporeal membrane oxygenation (ECMO) is initiated to bypass the cardiac system and bridge time to definitive treatment of the cardiac arrest (CA) origin. eCPR treatment is very time-critical and, if indicated, should be initiated as early as possible. Patient selection for this highly specific treatment is challenging and relies on numerous factors. In the following phase of intensive care treatment, neuroprognostication is performed. However, following current guidelines, this is only recommended 72hours after CA. Once ECMO is initiated, a complex intensive care treatment is expected, without a guarantee for full neurological recovery. There is a recognized clinical need for more precise selection criteria, alongside predictive values, to enable earlier, reliable neuroprognostication.\n\nAim This study aims to investigate whether super-early neuroprognostication before ECMO initiation is feasible. Super-early neuroprognostication will be performed using automated pupillometry and cerebral near-infrared spectroscopy (cNIRS) before ECMO initiation.\n\nMethods Patients evaluated for eCPR treatment at the Department of Emergency Medicine will be included in this study. By a study member not involved in clinical treatment, cNIRS and automated pupillometry will be performed before ECMO initiation and at predefined intervals: 10-20 minutes after ECMO Initiation, 1 hour (±15 minutes), 2 hours (±15 minutes), and 3 hours (±15 minutes). Follow-up measurements will be taken 24 hours (± 6 hours), 48 hours (± 6 hours), and 72 hours ± 6 hours after ECMO initiation. The secondary objective is to interpret the collected data regarding outcome parameters.",[524,525,526,527],"Resuscitation","Extra Corporeal Life Support","ECMO","Extracorporeal Cardiopulmonary Resuscitation",[529,526,530],"eCPR","CPR","2026-05-12",{"date":533,"type":34},"2026-05-14",{"date":531,"type":34},{"date":536,"type":23},"2028-10",{"name":40,"class":41},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":42},"100627676","multicpr-the-influence-of-resuscitation-on-history-recall-100627676","NCT07451730","MultiCPR: The Influence of Resuscitation on History Recall","MultiCPR4","Inclusion:\n\n* Healthy medical professionals trained in CPR (paramedics, prehospital emergency physicians, anesthesiologists, internal medicine doctors, nurses, midwifery students, pediatricians)\n* CPR Training in the last four years\n* Fit and rested.\n\nExclusion:\n\n\\- Pregnant probands",{"count":546,"type":23},38,[26],"In this randomized crossover trial, participants begin with chest compressions at a 30:2 ratio while a study team member provides ventilation. In Scenario A, participants perform two-person CPR and receive a prerecorded patient history after 30 seconds. In Scenario B, participants only listen to the patient's history without performing CPR or any concurrent task. To control for time-dependent memory decay, Scenario B includes a 3-minute delay before completing the questionnaire, matching the interval between information exposure and recall in Scenario A.\n\nAfter each scenario, participants complete the NASA-TLX workload assessment and a semi-open questionnaire on the patient's history. A modified Brown-Peterson task follows as a washout period: participants subtract 3 repeatedly from 309 for 1 minute, followed by 4 minutes of rest without phone use or conversation. Calculation performance is not analyzed.",[550],"Multitasking Behavior","2026-05-11",{"date":553,"type":34},"2026-05-13",{"date":555,"type":34},"2026-02-25",{"date":557,"type":23},"2026-11",{"name":40,"class":41},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":19,"minAge":567,"maxAge":430,"enrollmentInfo":568,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":42},"100633646","percutaneous-auricular-vagus-nerve-stimulation-with-conventional-rehabilitation-training-in-chronic-back-pain-patients-100633646","NCT07529392","Percutaneous Auricular Vagus Nerve Stimulation With Conventional Rehabilitation Training in Chronic Back Pain Patients","Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined With Conventional Rehabilitation Training to Improve Functional Outcome in Chronic Back Pain Patients (CURA): A Randomized Controlled Pilot Study","CURA","Inclusion Criteria:\n\n* Male or female aged ≥30 and ≤65 years\n* Indication: chronic myofascial\u002Fmusculoskeletal back pain\n* normal function of spinal nerves\n* Intractable pain for more than 6 months\n* Patient on oral pharmacotherapy ≤ WHO II with no adequate response or intolerant\n* Severity according to \"Leistungskategorie 2\" of BVAEB classification, which means Barthel Index 35-80, 6-minute walk test 300-480 m OR ergometry 50-80%\u002F0.75-1.25, ICF-Core-Sets grade 3\n* Average pain over the last 4 weeks according to painDETECT ≥ 4 and ≤ 9 at baseline\n* ODI 20-80 at baseline\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic back pain (trauma, fracture, tumor, infection, severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions)\n* Indication for back surgery\n* Radicular pain\n* Back surgery within the last 6 months\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, Metamizol, etc.)\n* Opioid analgesic therapy \\> WHO II\n* Underwent other physical therapy modalities for back pain, also TENS, 2 weeks before baseline\n* History of vagus nerve stimulation or electrical auricular stimulation\n* History of vasovagal syncope\n* High BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher)\n* Hemophilia or strong anti-coagulation medication\n* Autonomic disorders\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure\n* Major psychiatric comorbidity (at the discretion of the PI)\n* Other serious clinically relevant co-morbidity\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies\n* Infection, eczema, or psoriasis at application site (ear and neck)\n* Numbed and desensitized skin at the application site (ear and neck)\n* Chronic drug or alcohol abuse within the last 6 months\n* Pregnant or nursing female patients\n* Active implantable device\n* Open pension request\n* Currently participating in another clinical trial or participated over the last 3 months\n* Relevant change in concomitant treatment or medication during the study","30 Years",{"count":569,"type":23},48,[26],"The therapeutic action of aVNS in pain treatment is based on the masking of pain by the electrical stimulation pulses, the activation of inhibiting pain control systems, and the release of neurotransmitters, such as endorphins. Pairing VNS stimulation with exercise and physiotherapy has yielded beneficial results in stroke patients as well as in smaller studies with back pain patients, already in short periods of time (2-4 weeks).\n\nThe current study is intended to evaluate the performance of percutaneous auricular Vagus Nerve Stimulation (pVNS) in combination with Standard-of-Care (SoC) in a 3-week in-patient rehabilitation setting, in patients with chronic musculoskeletal\u002Fmyofascial back pain. This will be a prospective, open, randomized, controlled pilot study to evaluate pVNS using the VIVO® wearable medical device for personalized pain treatment, in terms of feasibility, efficacy, and safety in combination with rehabilitation training. Patients will be randomized into one of the following treatment groups:\n\n* Group A: VIVO® (pVNS) + SoC (treatment group)\n* Group B: SoC (control\u002Fcomparator group) Patients will remain on treatment for 3 weeks. This is comparable to other studies performed earlier, which showed safe and effective use of pVNS in chronic pain patients. The additional follow-up period of 3 weeks (optional 3 months and 6 months) allows to evaluate sustainable effects of treatment and late time effects, as previously shown in other studies.\n\nPatients in the treatment group (VIVO® + SoC) will receive personalized aVNS therapy in combination with SoC. Personalization of VIVO® treatment is performed based on the individual perception level of the stimulation at the ear with regards to the stimulation amplitude (in Group A). Amplitude is adjusted (range 0-5 V) to reach a distinct but comfortable tingling sensation to reach activation of Aβ-fibers of the auricular vagus nerve but not Aδ-fibers producing a sensation of pain. Not only the Investigator is able to adjust the amplitude at the trial visit (via VIVO® Pen) but also the patient is able to adjust the amplitude according to his\u002Fher perception.\n\nPatients will be randomized in this pilot study to receive either aVNS with the VIVO® system in addition to SoC vs. SoC alone as comparator group. Estimates of performance endpoints will thus be contrasted between aVNS and an established treatment option in this indication and controlled for regression to the mean and other forms of sampling bias.\n\nAll concomitant medication and therapies will be thoroughly documented and taken into account in the final analysis.",[573],"Chronic Back Pain",[575,576],"Percutaneous Auricular Vagus Nerve Stimulation","Rehabilitation","2026-04-21",{"date":579,"type":34},"2026-04-24",{"date":581,"type":34},"2025-11-27",{"date":583,"type":23},"2027-03-15",{"name":40,"class":41},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":592,"conditions":593,"keywords":595,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":42},"100540835","video-interpreting-in-prehospital-emergency-medicine---feasibility-study-100540835","NCT06322004","Video-Interpreting in Prehospital Emergency Medicine - Feasibility Study","Inclusion Criteria:\n\n* adult patients, at least 18 years old\n* awake, responsive patients\n* language barrier (Albanian, Dari, Romanian, Turkish, Modern Standard Arabic, Arabic, Farsi, Russian, Hungarian, Bosnian-Croatian-Serbian, Kurdish (Kurmanci), Slovakian, Bulgarian, Polish, and Czech)\n\nExclusion Criteria:\n\n* unconscious patients\n* out-of-hospital cardiac arrest patients\n* delay of treatment or transportation due to e-interpreting\n* refusal of video-interpreting by the patient",{"count":362,"type":23},"50 responsive patients with language barriers will be included in this study. The prehospital emergency physician will start video-interpreting via a tablet. Feasibility, quality of communication, usability as well as changes in diagnosis and treatment will be gathered and analysed.",[594],"Communication Barriers",[596,597,598,599],"Communication barriers","Prehospital emergency medicine","Emergency medicine","Emergency physician","2026-04-15",{"date":602,"type":34},"2026-04-20",{"date":604,"type":34},"2023-02-06",{"date":606,"type":23},"2026-12-31",{"name":40,"class":41},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":24,"phases":617,"briefSummary":618,"conditions":619,"keywords":621,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":281},"100632692","intramuscular-injection-of-mashed-parathyroid-tissue-into-a-forearm-during-thyroid-surgery-to-prevent-permanent-postoperative-parathyroid-insufficiency-imipat-study-100632692","NCT07516990","Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoperative Parathyroid Insufficiency (IMIPAT Study)","Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoperative Parathyroid Insufficiency (IMIPAT Study) - a Prospective Multicentre Trial","IMIPAT","Inclusion Criteria:\n\n* signed informed consent\n* parathyroid autotransplantation in forearm performed during thyroid surgery\n* 18 years of age and above\n\nExclusion Criteria:\n\n* under 18 years of age\n* informed consent not signed\n* hyperparathyroidism\n* no parathyroid autotransplantation performed",{"count":138,"type":23},[26],"Parathyroid insufficiency is a common complication in thyroid surgery and occurs in 6.6 to 24%. Up to 4.4% suffer from permanent hypoparathyroidism requiring life-time substitution of calcium and vitamin D in order to maintain a normal calcium homeostasis. To prevent permanent postoperative parathyroid insufficiency after thyroidectomy, devascularized parathyroid glands are re-implanted intramuscularly by standard. To achieve graft function, meticulous preparation and division of parathyroid tissue is necessary as a prerequisite for tissue nutrition by diffusion until a recapillarization of the parathyroid fragments sets in. There are persistent controversies about the optimal technique for the autotransplantation. The injection of mashed parathyroid tissue into a muscle appears to be a fast, secure and easy tech-nique to provide a sufficient parathyroid hormone (PTH) production in cases of insufficient production of the glands left in-situ. The study is based on the hypothesis that intramuscular injection of mashed parathyroid tissue is a safe procedure that enables graft survival through diffusion and allows for the subsequent production of systemically measurable levels of parathyroid hormone (PTH). The intervention consists of injecting mashed parathyroid tissue into the brachioradialis muscle of the non-dominant arm. The primary objective is to evaluate this technique with respect to both local complications arising from the transplantation procedure and the functional performance of the graft over time. Outcome measures include the PTH gradient between the transplanted and non-transplanted arms, parathyroid hormone levels measured in the antecubital fossa of both arms, and calcium levels. The study population comprises 100 patients, and the trial is designed as a prospective multicentre study. The risk-benefit assessment indicates that the risks associated with participation-particularly local complications and potential graft malfunction-are expected to be low. In patients with familial or renal hyperparathyroidism, autotransplantation of small parathyroid fragments (approximately 1 mm in diameter) has been standard practice for decades. Additionally, the injection of mashed parathyroid tissue into the sternocleidomastoid muscle during surgery has been performed in many centers for years. However, that approach has the limitation that PTH originating from the graft cannot be reliably measured due to anatomical constraints.",[620],"Graft Function",[622,623,624],"graft function","parathyroid autotransplantation","postoperative hypothyroidism","2026-04-14",{"date":627,"type":34},"2026-04-17",{"date":629,"type":23},"2026-04-02",{"date":631,"type":23},"2027-04-01",{"name":40,"class":41},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":642,"briefSummary":643,"conditions":644,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":651,"locationsCount":42},"100634194","measurement-of-ocular-blood-flow-and-retinal-oxygen-extraction-in-diabetic-patients-100634194","NCT07536516","Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients","DM OPF ROXY","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Signed informed consent\n* Previously diagnosed diabetes mellitus\n* Normal ophthalmic findings except diabetic retinopathy, unless the investigator considers an abnormality to be clinically irrelevant\n* Planned initiation of therapy with GLP-1 receptor agonist (Semaglutide, Ozempic®; Liraglutide, Victoza®) or GIP\u002FGLP-1 receptor agonist (Tirzepatide, Mounjaro®) by a diabetes specialist\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the 3 weeks preceding the screening visit\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Blood donation during the previous three weeks\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Previous laser photocoagulation treatment in the study eye\n* Best corrected visual acuity \\\u003C 0.4 Snellen\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception\n* Pregnancy, planned pregnancy or lactation",{"count":641,"type":23},20,[26],"The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP\u002FGLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP\u002FGLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.",[645],"Diabetes Mellitus","2026-04-10",{"date":627,"type":34},{"date":649,"type":34},"2025-11-28",{"date":392,"type":23},{"name":40,"class":41},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":660,"enrollmentInfo":661,"targetDuration":4,"studyType":24,"phases":663,"briefSummary":664,"conditions":665,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":42},"100555455","personalized-targeted-glioblastoma-therapies-by-ex-vivo-drug-screening-100555455","NCT06512311","Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening","Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial (ATTRACT)","ATTRACT","Inclusion Criteria:\n\n* Age 18-75\n* ECOG performance status 0-2\n* Newly diagnosed glioblastoma, IDH wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System\n* MGMT promotor unmethylated per local investigator\n* Tissue available for drug screening (successful PDC establishment from surgical material)\n* Scheduled for concomitant radio-chemotherapy with temozolomide\n* Written informed consent\n\nExclusion Criteria:\n\n* Current participation in another therapeutic clinical trial\n* Patients with a concurrent malignancy or malignancy within five years prior of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years\n* Pregnant or lactating women\n* Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody \\[HBsAg\\] test and a positive anti-hepatitis B core antibody \\[HBcAb\\] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n* Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells\u002Fmm3 , no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.\n* Any of the following co-morbidities:\n\n  * Pre-existing severe peripheral neuropathy (\\> CTCAE grade 2)\n  * Hepatic impairment (Bilirubin Level \\>1.5x-3x ULN)\n  * Kidney dysfunction (CrCl \\\u003C 59 mL\u002Fmin)\n  * Cardiac dysfunction with left ventricular ejection fraction \\\u003C60 %\n  * Any grade of interstitial lung disease\n  * Ongoing or previous history of rhabdomyolysis\n  * Acute pancreatitis\n  * QTcF ≥480 msec\n  * Diabetes mellitus with fasting glucose \\> 250mg\u002Fdl or 13.9 mmol\u002FL\n* Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.","75 Years",{"count":662,"type":23},240,[26],"Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.",[666],"Glioblastoma","2026-04-09",{"date":625,"type":34},{"date":670,"type":34},"2024-07-10",{"date":672,"type":23},"2031-12-31",{"name":40,"class":41},""]